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Abstract
Background—Low adherence to oral bisphosphonates is a common problem that jeopardizes the 
efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance 
is widely accepted in these patients.
Methods—The International Osteoporosis Foundation and the European Calcified Tissue Society 
have convened a working group to propose a screening strategy to detect a lack of adherence to 
these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and 
CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating 
oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this 
question and were used as the basis for testing the hypothesis.
Results—Based on the findings of the TRIO study, specifically addressing this question, the 
working group recommends measuring PINP and CTX at baseline and three months after starting 
therapy to check for a decrease above the least significant change (decrease of more than 38% for 
PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, 
if variation in at least one is considered when measuring both, the level of detection is 94.5%.
Conclusions—If a significant decrease is observed the treatment can continue but if no decrease 
occurs the clinician should reassess to identify problems with the treatment, mainly low adherence
Keywords
Adherence; Bisphosphonates; Osteoporosis treatment; Screening; Position paper
Introduction
Oral bisphosphonates are a first line treatment for osteoporosis. However, as in any other 
chronic diseases, low adherence is a common clinical problem. It has been observed that the 
adherence to oral bisphosphonates is as low as 59 (1) or 43% (2) at one year and appears to 
be worse with generic medications (3). This problem significantly jeopardizes the anti-
fracture efficacy and cost effectiveness (4). Few interventions to improve adherence have 
been tested, and the ones that may be effective include education programs (5, 6).
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Monitoring adherence is the first step in managing this problem since it detects those 
patients with problems with the medication. The response of bone turnover markers to 
therapy, in the individual patient, is one of the methods suggested for treatment monitoring 
(7). Their advantage is that they are widely available, affordable and clinicians are familiar 
with their interpretation. They reflect the early effect of the drug on bone tissue (8). Low 
response may be detected shortly after treatment has been started and may indicate low 
adherence, low bioavailability, interactions with other drugs or the presence of secondary 
osteoporosis (9). Moreover, bone turnover marker response has been used as an intervention 
for improving treatment adherence(5) (10).
Serum PINP (Procollagen type I N- terminal propeptide) and CTX (Collagen type I C-
terminal telopeptide) have been recommended as reference markers by a committee of the 
International Osteoporosis Foundation (IOF) and the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) (8). Oral bisphosphonates decrease levels of 
PINP and CTX rapidly in most patients, beyond the least significant change (LSC), the 
margin of change as demonstrated from the results of a recent controlled trial (11). 
Therefore they are an excellent candidate for screening treatment effect early after starting 
the drug and may detect any problem with adherence.
The aim of the present work is to establish a clinically feasible and practical strategy, based 
on bone turnover marker measurement, to detect a lack of response which may indicate a 
problem with adherence to oral osteoporosis drugs, specifically amino bisphosphonates, and 
give a recommendation for their use in clinical practice in the individual patient. For this the 
International Osteoporosis Foundation and the European Calcified Tissue Society have 
convened a working group to answer this question.
Methods
The Working Group (WG) proposed the following question: Can the bone turnover markers 
(BTMs) PINP and CTX be used to identify low adherence in patients with postmenopausal 
osteoporosis initiating oral bisphosphonates for osteoporosis?
Bone turnover markers
Measurement of bone turnover markers is considered as the most specific early method for 
measuring the biological effect of bisphosphonates. The WG focused on the two markers 
prioritized by the IOF, namely serum CTX and PINP.
It is necessary to know what proportion of patients with osteoporosis has changes in these 
markers that exceed the least significant change when taking oral bisphosphonate therapy. 
This proportion provides the detection rate of the test (i.e., the sensitivity). The least 
significant change is defined here as the 95% confidence bounds for change in patients 
treated with bisphosphonates for 12 weeks; thus, only 2.5% of untreated patients would 
exceed the least significant change (the false positive rate). Responders are considered as 
those patients who show changes in BTMs that exceed the LSC. The levels established for 
LSC were 56% decrease for CTX and 38% decrease for PINP (11). Two measurements of 
bone turnover markers, at baseline and three months after the prescription, are 
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recommended. This 3 month interval is long enough to be able to detect the change, is 
acceptable to the patient and represents the period during which treatment is often 
discontinued (12). Where baseline levels were not available, ‘response’ was also considered 
if the BTM were below the premenopausal mean (32 ng/L for CTX and 28 ug/L for PINP).
Analysis of the TRIO Study
The primary source of information to establish the reference values for response rate is the 
TRIO study (11, 13). The TRIO study was so named as it was a study of three drugs (a trio 
of drugs). Under conditions of a controlled clinical trial, the results of the TRIO study can be 
assumed to be a benchmark for response of turnover markers.
The TRIO study was a single-center randomized controlled trial of three oral 
bisphosphonates (alendronate, ibandronate and risedronate) at their licensed doses to study 
their effect on bone turnover markers and bone mineral density in postmenopausal 
osteoporosis. The study specifically addresses the proportion of patients initiating oral 
bisphosphonates that show decreases in BTMs beyond the LSC after three months of 
therapy. The least significant change used was 2-tailed, p<0.05, thus we can be 95% sure 
that a change (up or down) as large as this, or larger, is significant. Furthermore, to minimize 
variability standardized sample collection, appropriate instructions to the patient and 
exclusion of individuals with fracture in the preceding 12 months were applied. We have 
focused on 3 months for simplicity, but the window could be widened, especially for PINP, 
and in an unpublished analysis we found that a later measurement did not affect the results.
The TRIO study included 172 women with postmenopausal osteoporosis ages 53-84 who 
were treated for up to 2 years. There was a concurrent (non-randomized) control group of 87 
premenopausal women ages 35 to 40 years. Women with osteoporosis were entered into an 
open label, parallel, randomized intervention with the three commonly-used oral 
bisphosphonates, alendronate, ibandronate and risedronate (11) along with calcium and 
vitamin D supplementation.
Blood was taken in the fasting state between 0800 and 1000 before any supplement was 
given (-1 week), one week on supplement (0 week) and after starting bisphosphonates (1, 2, 
4, 12, 13, 48 and 96 weeks). This analysis will use the -1 week as baseline and the average 
of the 12 and 13-week samples for on treatment. Biochemical measurements included serum 
CTX and PINP using the IDS iSYS automated immunoassay platform. All specimens were 
collected fasting, frozen at -80aC and were measured in one analytical batch. Many other 
measurements were made of biochemical variables as well as bone density, but these are not 
included here.
Adherence was evaluated by the Medication Event Monitoring System (MEMS) caps. Good 
adherence was defined as taking more than 80% of tablets over 48 weeks.
Detection rate
An additional analysis on the TRIO results was performed to identify the proportion of 
patients receiving oral bisphosphonates that show decreases in each of the two proposed 
markers, CTX and PINP, as well as the proportion of cases that showed this change with 
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either one of the other. From this, we calculated the detection rate for a single marker and for 
both markers, considering decrease in at least one of the markers beyond the LSC as a 
positive test.
The formula for calculating detection rate was:
‘positives’ describe the cases showing a decrease > LSC in one or both markers; ‘negatives’ 
describe the cases with no change or a change less than the LSC.
Results
The characteristics of the TRIO population are described in detail in the original publication 
[13]. In Table 1 are summarized the baseline values for each of the treatment groups, the 
values after three months of treatment and the percentage of decrease in CTX and PINP each 
for each drug (see also Figure 1).
Good adherence, defined as taking more than 80% of tablets over 48 weeks, was found in 
104/135 subjects who completed 48 weeks. This was associated with a 79% decrease in 
CTX as compared to low adherence, which was associated with a 64% decrease. Also it was 
associated with a 67% decrease in PINP as compared to low adherence, which was 
associated with a 51% decrease. However, it has to be pointed out that the relationship 
between adherence and response to BPs is not a simple linear one and very low adherence is 
necessary to have no response (Table 2).
Responders were considered as those cases with a decrease in markers more than the LSC, 
based on a decrease in CTX of 56% and a decrease in PINP of 38%. The lumbar spine BMD 
(bone mineral density) increase at 96 weeks in CTX responders was 6.0% and 1.3% in non-
responders. The total hip BMD increase at 96 weeks in CTX responders was 3.2% and 1.0% 
in non-responders. The lumbar spine BMD increase at 96 weeks in PINP responders was 6.2 
and 2.3% in non-responders. The total hip BMD increase at 96 weeks in PINP responders 
was not different to non-responders. All these changes were independent on baseline values 
of turnover markers. Responders were considered those cases with a decrease in markers 
more than the LSC.
The average decrease for CTX ranged from 68 to 81% and for PINP between 48 and 63% 
for the different treatment arms. For the different bisphosphonates, the percentage of 
individuals with a decrease beyond the LSC ranged from 78 to 98% for CTX and between 
75 and 94% for PINP (Table 1).
Table 3 summarizes the detection rate for the overall cohort, that is, the percentage of 
individuals in the overall cohort that show a decrease in CTX, PINP, beyond the LSC, or at 
least in one of them if both are measured, after three months of initiating therapy. For CTX 
the detection rate reaches a 87%, for PINP 84% and, if decrease in at least one is considered 
when measuring both, the level of detection is 94.5% (Table 3). This means that the patients 
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are taking and responding to the medication. Based on these results, a screening strategy is 
proposed as summarized in Figure 2. In brief, after measuring bone turnover markers before 
initiating medication, a second measurement is performed at three months. If the decrease 
does not exceed the LSC the clinician should reassess the treatment, mainly the adherence 
and, eventually, if an underlying cause of secondary osteoporosis or low response to the drug 
has not been previously detected.
A ‘response’ was also considered if the BTM were below the premenopausal mean (which 
was 32 ng/L for CTX and 28 ug/L for PINP). The baseline CTX and PINP were above these 
thresholds in 91 and 89% of women, respectively. The CTX values after 12 weeks of 
treatment were below these thresholds in 86%, 96% and 83% for ibandronate, alendronate 
and risedronate, respectively. . The PINP values after 12 weeks of treatment were below 
these thresholds in 96%, 82% and 75% for ibandronate, alendronate and risedronate, 
respectively. This approach is useful if there is no baseline BTM available.
In practice, we wouldn’t usually repeat the measurement of CTX and PINP at both 12 and 
13 weeks on treatment. In an unpublished analysis, we checked whether the responder rates 
were the same with just the 12-week measurement and whether we defined response by the 
least significant change or by being below the premenopausal mean, the number responding 
was only 1 to 3% fewer.
Discussion
The working group recommends a screening policy for assessing adherence to oral 
bisphosphonates given as treatment for osteoporosis, by measuring PINP and CTX three 
months after starting therapy. At this time-point we would only expect 2.5% of untreated 
patients to exceed the least significant changes of 56% for CTX and 38% for PINP, yet with 
the oral bisphosphonate therapy overall, we found that 75-98% of women responded.
This strategy fulfills the requirements for a screening procedure. A screening test needs to 
offer a high detection rate and perform well when the incidence of a condition in a given 
population is high. Accordingly, it is well known that patients treated with oral 
bisphosphonates have a good response in turnover markers. Moreover, a screening test has to 
be easy to perform, widely available, cheap, common practice and needs to show a high 
sensitivity (detection rate). In other words, the detection rate for the decrease of BTMs 
(beyond the LSC) should be very high to minimize the proportion of false negative tests. 
Therefore, the present recommendations are in accordance with all these principles and can 
be translated to clinical practice.
We use the statistic ‘detection rate’. Detection rate has been considered as synonymous with 
sensitivity (14) although these concepts are not identical. For calculating sensitivity a gold 
standard test is needed and, from that, a 2x2 table can be built and sensitivity estimated. For 
the clinical assessment of the exposure of bone tissue to a drug, biochemical markers are the 
gold standard since obtaining bone biopsies is not acceptable and, moreover, in the largest 
series the correlation between markers and histomorphometry is moderately strong (15). 
Moreover, bone histomorphometry predicts fracture in children poorly (16) and biochemical 
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and histomorphometric indexes correlate moderately well in adults treated with denosumab 
(17) or teriparatide (18).
The objective of the TRIO study used here as the basis for our analysis was perfectly in 
accordance with the required information needed for developing the current 
recommendations. The data comprises the three first-line (and most prescribed) oral 
bisphosphonates used for treating osteoporosis, at their licensed doses. In another 
publication, Sebba et al. used the biochemical marker changes as response indicators (19) 
from the FACT (Fosamax Actonel Comparison Trial) study. They defined a CTX response 
of 60% and a PINP response of 50% as significant although they didn't provide any evidence 
for these cut-offs. The response rate detected by CTX at 3 months was 70% for alendronate 
and 40% for risedronate whereas for PINP was 77 and 50%. The lower responder rate in 
FACT is likely to be due to less use of calcium and vitamin D supplements in that study as 
well as the greater estimates of LSC.
Indeed the required variation in the individual patient should exceed the least significant 
change value, and this is the basis for making the clinical judgment about low adherence or 
underlying causes of impaired response such as undiagnosed secondary osteoporosis or 
medications that interfere with the effect of the drug (20). The LSC thresholds of the TRIO 
study here used (11) are comparable with those previously reported in the literature as 
summarized in Table 4 (21–23). In the field of bone densitometry, it is regarded as good 
practice by the Internataion Society for Clinical Densitometry for each clinical centre to 
establish its own least significant change. This may be too onerous in practice to obtain for 
bone turnover markers.
The results of the TRIO study also offer strength to the clinical recommendations because 
they represent the benchmark of what can be achieved in clinical practice from a controlled 
trial where the monitoring and adherence are the best that can be obtained. The timing for 
assessment, three months after prescription (decision to treat) and in most cases acceptance 
(start of the therapy), is optimal because the changes in the markers are already complete 
although the same performance of the screening can be expected if for some reason the 
second measurement is made later on, at six or even 12 months. The three month 
measurement is early enough to assess how the patient accepts and tolerates the treatment 
and also covers the critical period of primary non-adherence, in the first weeks after the 
prescription is given when patients may have discontinued treatment or may never have 
started (12). Some limitations should be also mentioned. The results of the TRIO study refer 
to postmenopausal women in a given geographical area and, therefore, their translation to 
men and premenopausal patients as well as to other areas has to be extrapolated. 
Furthermore, the small number of participants is another limitation although TRIO is a study 
that specifically addresses our research question. We found no systematic study on men and 
young women and so we could speculate that they would have the same response rate. 
However, more research on this aspect is needed and further validation of the results 
obtained in the TRIO study in different clinical trials and/or different drugs must be obtained 
to fully certify the proposed strategy.
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Moreover, the results in real world practice are always expected to be worse, in terms of 
adherence, than what is observed in a clinical trial. However, this is why the TRIO results 
should be considered as a benchmark of the best possible scenario under ideal conditions of 
practice. The cost of the test, in settings where are not covered by reimbursement policies, 
may be another practical limitation. Finally, the biological variability of CTX is quite large 
when it is evaluated in a sufficiently large population.
There is an alternative way to evaluating treatment response that was described for the TRIO 
study. Sometimes we don't have a baseline BTMs result. It would appear that most patients 
before treatment are above the average value for young women and most women on 
treatment are below this value. Thus, a second approach to identifying response could be to 
measure BTMs on treatment and if the value is below the young normal mean (e.g. PINP 35 
ug/L, CTX 25 ng/L) then consider that adequate suppression of bone turnover that wouldn't 
happen if treatment was not taken. However, we believe that not having baseline 
determinations of bone markers adds uncertainty and makes hard to apply this screening 
strategy.
Can other commonly used assays for CTX and PINP (such as the assays offered by Roche 
Diagnostics) be used in the samem way as the IDS assays used in TRIO? We don’t know of 
any side by side comparison of serum CTX and PINP by the IDS and other assays for 
treatment response. However, the antibody used by the two suppliers of CTX assays are the 
same, so it is likely that the percentage response and probably the LSC will be similar. The 
PINP assays from IDS and Roche do differ in that the IDS measures only intact PINP 
whereas Roche measures both the intact and the monomer forms. However, this doesn’t 
seem to affect the absolute value of the PINP and only seems to be a problem in end-stage 
renal disease.
The working group does not suggest that this screening strategy will have a direct impact on 
adherence. It may be interesting to further evaluate whether these recommendations have an 
impact on medication adherence in a real-life setting, considering also the cost-effectiveness 
balance. Adherence is a complex issue and interventions address the specific perceptions 
(e.g. patient’s beliefs about osteoporosis and its treatment) and practicalities (e.g. capability 
and resources) influencing the motivation and ability to start and continue with the 
treatment. (24) However, assessing adherence is a crucial first step to any intervention and 
the feedback to the patient has to ensure a no-blame approach and be made in the context of 
their behavior and beliefs characteristics.
Bone densitometry is the most commonly used method for measuring the effect of 
treatments in clinical practice and its value for defining the goal of therapies is currently one 
of the hot topics in the field. However the time required for detecting a significant variation 
is considerably longer than for biochemical markers. This fact limits the clinical utility of 
BMD monitoring for an early assessment of the effect of oral bisphosphonates, precisely 
when most of the adherence problems occur.
In summary, the Working Group proposes measurement of PINP and CTX levels at baseline 
and after three months of initiating treatment. In those individuals where the decrease does 
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not exceed the least significant change (38 and 56%, respectively) assessment of adherence 
or, eventually, investigation of secondary osteoporosis (9), should be carried out.
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Mini Abstract
Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the 
response of biochemical markers of bone turnover after three months of therapy. If no 
change is observed, the clinician should reassess the adherence to the treatment and also 
other potential issues with the drug.
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Figure 1. 
1 Change from baseline after three months of treatment with the three tested 
bisphosphonates (Ibandronate, Alendronate and Risedronate) in CTX (upper panel) and 
PINP (lower panel). Shadowed zone indicates change > least significant change for the 
marker
Ibn= Ibandronate; Aln = Alendronate; Ris = Risedronate
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Figure 2. 
Algorithm for the assessment of adherence based on the measurement of CTX and/or PINP
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Table 1
Values of biochemical markers at baseline and after three months of treatment and percentage of decrease for 
each of the treatment groups
Ibandronate Alendronate Risedronate Young controls
N 57 57 58 87
CTX, ng/mL, mean baseline 0.68 0.64 0.59 0.32
CTX response, 3 months, % decrease 73 81 68 --
% of CTX responders, 3 months* 84 98 78 --
PINP, ng/mL, mean baseline 49.9 46.2 44.0 29.0
PINP response, 3 months, % decrease 63 56 48 --
% of PINP responders, 3 months* 94 82 75 --
*% of patients with a decrease at three months > least significant change (LSC). LSC based on CTX values was defined as a decrease of 56%, 
based on PINP by 38%
Thus, with serum CTX 78-98% of women, and with serum PINP 75-94% of women are considered 'responders' after 3 months of treatment, 
depending on the bisphosphonate used.
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Table 2
Relationship between adherence* and response to daily treatment with oral risedronate (25)
Tablets taken Mean % change Responders, %
<26 -36 56
26-52 -42 59
52-78 -49 72
78-104 -62 64
>104 -63 87
*Adherence measured at 48 weeks. Responders are considered the individual patients that show changes in BTMs that exceed the LSC.
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Table 3
Detection rate as percent of cases in the overall cohort with the prespecified decrease>LSC in CTX, PINP or 
both after the initiation of treatment
BTM N N with decrease>LSC N with decrease<LSC Detection rate (%)
CTX 146 127 19 86.9
PINP 149 125 24 83.9
CTX+PINP 146 138 8 94.5
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Table 4
LSC thresholds of the TRIO study compared with those previously reported
BTM LSC %
Naylor OI 2015 (11) Fink OI 2000 (26) Hannon JBMR 1998 (22) Rogers Bone 2009 (23)
CTX 56 57 67 28
PINP 38 38 40 25
The methods used were: Naylor automated (IDS), Fink, Hannon and Rogers manual assays.
The only estimate of the LSC we have found was for CTX of 27% (27) (Garnero 2001) and PINP of 20% (28) (Garnero 2008) on the Roche 
Elecsys.
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